Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| ciliated cell | 13 studies | 31% ± 14% | |
| classical monocyte | 12 studies | 22% ± 7% | |
| endothelial cell | 11 studies | 26% ± 11% | |
| fibroblast | 8 studies | 22% ± 8% | |
| basal cell | 7 studies | 24% ± 7% | |
| macrophage | 7 studies | 22% ± 7% | |
| epithelial cell | 7 studies | 38% ± 21% | |
| neuron | 6 studies | 30% ± 14% | |
| abnormal cell | 6 studies | 24% ± 10% | |
| hematopoietic precursor cell | 5 studies | 23% ± 5% | |
| monocyte | 5 studies | 24% ± 4% | |
| non-classical monocyte | 5 studies | 28% ± 9% | |
| pericyte | 5 studies | 19% ± 2% | |
| oligodendrocyte precursor cell | 5 studies | 28% ± 11% | |
| natural killer cell | 5 studies | 19% ± 2% | |
| goblet cell | 5 studies | 24% ± 6% | |
| plasmablast | 4 studies | 42% ± 17% | |
| secretory cell | 4 studies | 19% ± 2% | |
| squamous epithelial cell | 4 studies | 36% ± 21% | |
| glutamatergic neuron | 4 studies | 31% ± 12% | |
| astrocyte | 4 studies | 22% ± 5% | |
| interneuron | 4 studies | 29% ± 11% | |
| CD16-positive, CD56-dim natural killer cell, human | 4 studies | 18% ± 2% | |
| myofibroblast cell | 4 studies | 17% ± 1% | |
| smooth muscle cell | 4 studies | 18% ± 3% | |
| B cell | 4 studies | 20% ± 6% | |
| type I pneumocyte | 4 studies | 27% ± 5% | |
| GABAergic neuron | 4 studies | 28% ± 12% | |
| naive B cell | 4 studies | 18% ± 1% | |
| plasmacytoid dendritic cell | 4 studies | 21% ± 5% | |
| respiratory goblet cell | 3 studies | 32% ± 14% | |
| pancreatic A cell | 3 studies | 49% ± 27% | |
| conventional dendritic cell | 3 studies | 32% ± 8% | |
| common myeloid progenitor | 3 studies | 22% ± 8% | |
| myeloid cell | 3 studies | 32% ± 2% | |
| pro-B cell | 3 studies | 25% ± 6% | |
| type II pneumocyte | 3 studies | 23% ± 9% | |
| dendritic cell | 3 studies | 35% ± 12% | |
| enteroendocrine cell | 3 studies | 28% ± 9% | |
| transit amplifying cell | 3 studies | 22% ± 5% | |
| oligodendrocyte | 3 studies | 18% ± 3% | |
| erythroblast | 3 studies | 28% ± 10% | |
| T cell | 3 studies | 21% ± 5% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| esophagus | 100% | 18606.33 | 1445 / 1445 | 100% | 248.57 | 183 / 183 |
| ovary | 100% | 20265.83 | 180 / 180 | 100% | 344.39 | 430 / 430 |
| prostate | 100% | 16622.41 | 245 / 245 | 100% | 216.11 | 502 / 502 |
| skin | 100% | 20518.47 | 1809 / 1809 | 100% | 244.18 | 472 / 472 |
| stomach | 100% | 12419.03 | 359 / 359 | 100% | 234.19 | 286 / 286 |
| thymus | 100% | 26647.60 | 653 / 653 | 100% | 253.08 | 605 / 605 |
| uterus | 100% | 21493.39 | 170 / 170 | 100% | 255.65 | 459 / 459 |
| breast | 100% | 16667.68 | 459 / 459 | 100% | 256.69 | 1116 / 1118 |
| intestine | 100% | 15872.95 | 966 / 966 | 100% | 231.95 | 526 / 527 |
| bladder | 100% | 16275.29 | 21 / 21 | 100% | 214.15 | 503 / 504 |
| lung | 100% | 17837.82 | 578 / 578 | 100% | 193.21 | 1152 / 1155 |
| adrenal gland | 100% | 23951.15 | 258 / 258 | 100% | 193.53 | 229 / 230 |
| brain | 99% | 13454.51 | 2628 / 2642 | 100% | 219.39 | 705 / 705 |
| kidney | 100% | 17523.22 | 89 / 89 | 99% | 153.93 | 895 / 901 |
| liver | 100% | 9153.74 | 225 / 226 | 99% | 111.07 | 402 / 406 |
| pancreas | 99% | 7610.59 | 326 / 328 | 99% | 179.04 | 176 / 178 |
| adipose | 100% | 15829.51 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 175.65 | 80 / 80 |
| lymph node | 0% | 0 | 0 / 0 | 100% | 283.96 | 29 / 29 |
| muscle | 100% | 19205.48 | 803 / 803 | 0% | 0 | 0 / 0 |
| spleen | 100% | 20089.66 | 241 / 241 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 100% | 199.59 | 45 / 45 |
| ureter | 0% | 0 | 0 / 0 | 100% | 114.83 | 1 / 1 |
| blood vessel | 100% | 15823.08 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| peripheral blood | 98% | 16664.85 | 914 / 929 | 0% | 0 | 0 / 0 |
| heart | 98% | 11515.92 | 845 / 861 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0006974 | Biological process | DNA damage response |
| GO_0016567 | Biological process | protein ubiquitination |
| GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
| GO_0000792 | Cellular component | heterochromatin |
| GO_0010008 | Cellular component | endosome membrane |
| GO_0030057 | Cellular component | desmosome |
| GO_0070062 | Cellular component | extracellular exosome |
| GO_0030867 | Cellular component | rough endoplasmic reticulum membrane |
| GO_0005739 | Cellular component | mitochondrion |
| GO_0005654 | Cellular component | nucleoplasm |
| GO_0005829 | Cellular component | cytosol |
| GO_0005765 | Cellular component | lysosomal membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0005634 | Cellular component | nucleus |
| GO_0004839 | Molecular function | ubiquitin activating enzyme activity |
| GO_0005515 | Molecular function | protein binding |
| GO_0005524 | Molecular function | ATP binding |
| GO_0003723 | Molecular function | RNA binding |
| Gene name | UBA1 |
| Protein name | Ubiquitin like modifier activating enzyme 1 Ubiquitin-like modifier-activating enzyme 1 (EC 6.2.1.45) (Protein A1S9) (Ubiquitin-activating enzyme E1) SUMO-activating enzyme subunit 1 (Ubiquitin-like 1-activating enzyme E1A) |
| Synonyms | UBE1 A1S9T |
| Description | FUNCTION: Catalyzes the first step in ubiquitin conjugation to mark cellular proteins for degradation through the ubiquitin-proteasome system . Activates ubiquitin by first adenylating its C-terminal glycine residue with ATP, and thereafter linking this residue to the side chain of a cysteine residue in E1, yielding a ubiquitin-E1 thioester and free AMP . Essential for the formation of radiation-induced foci, timely DNA repair and for response to replication stress. Promotes the recruitment of TP53BP1 and BRCA1 at DNA damage sites . . |
| Accessions | Q5JRR6 P22314 ENST00000451702.2 ENST00000442035.5 ENST00000377351.8 [P22314-1] ENST00000377269.3 Q5JRS2 ENST00000457753.5 ENST00000427561.5 ENST00000412206.5 Q5JRS1 ENST00000335972.11 [P22314-1] Q5JRR9 Q5JRS0 Q5JRS3 |